BioSpace News Archive

Cantargia Cantargia announced its interim report for the fourth quarter and year-end 2023.

Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, decisively continued on its profitable growth course in the financial year 2023 with an organic revenue growth of 10.4% and a strong adjusted EBITDA growth of 17.5%.

Indivior PLC announced its financial results for the period ending December 31, 2023.

Poolbeg Pharma announces that it has received notification that on 21 February 2024, Jeremy Skillington, Chief Executive Officer of the Company, purchased 154,764 ordinary shares at a price of 10.8 pence per share.

BioInvent International 2023 was a landmark year for BioInvent with positive clinical readouts from three Phase 1/2 programs.

Photocure ASA announces that its partner Asieris Pharmaceuticals has communicated that the international multicenter Phase III clinical study of Cevira®, the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions, will be presented for the first time in the form of an oral presentation at the 2024 European Research Organization on Genital Infection and Neoplasia, held March 13-16 in Stockholm, Sweden:

IRLAB Therapeutics AB announced that the company’s recent End-of-Phase 2 meeting with the US Food and Drug administration, FDA, was held in a constructive and engaging spirit.

LenioBio announced the appointments of Kathrin Knauf as Chief Technology Officer and Malene Linderoth as Chief Commercial Officer.

Medivir AB announced that clinical pharmacokinetic data on dose linearity and systemic exposure from the first study with fostroxacitabine bralpamide will be presented at the European Association for the Study of the Liver Liver Cancer Summit on February 23, 2024, in Rotterdam.

Telix Pharmaceuticals Limited announces its results for the financial year ended 31 December 2023.